Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Educating physicians about PSA reduction goals may increase the number of patients with mCSPC receiving first-line treatment ...

Androgen receptor non-canonical domain binding degrader for treatment of relapsed, refractory castration-resistant prostate cancer: K. Sadasivan Pillai Wednesday, March 5, 2025, 0 ...

Qingdao Putaike Biomedical Technology Co. Ltd. has described androgen receptor full length (AR-FL) and/or androgen receptor variant 7 (AR-v7) degradation inducers reported to be useful for the ...

Updated results from the TALAPRO-2 trial “support talazoparib plus enzalutamide as a standard-of-care initial treatment option for patients with mCRPC,” according to Neeraj Agarwal, MD.

Haisco Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an androgen receptor (AR) ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...